{
  "abstract": "Aims: To assess hepatic safety for adults with pexidartinib-treated tenosynovial giant cell tumor (TGCT) from the 6-year retrospective evaluation of the TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) Program.\n\nMethods: Retrospective hepatic safety data (08/2019–08/2025) were collected from healthcare professionals and patients in the tREMS Program.\n\nResults: During the current reporting period (06/2024–08/2025), 133/145 (91.7%) new patients received ≥1 pexidartinib dispense. For the cumulative 6-year reporting period, 878/929 (94.5%) patients received ≥1 pexidartinib dispense. Overall, 51/878 (5.8%) patients had adverse events or laboratory abnormalities suggesting serious and potentially fatal liver injury; of these, 47 (92.2%) discontinued pexidartinib, 3 (5.9%) interrupted doses, and 1 (2.0%) continued at the same dose. By August 2025, 34 (66.7%) events were fully resolved, 6 (11.8%) were resolving, 9 (17.6%) were unresolved, and 2 (3.9%) had unknown outcomes. There were no cases of irreversible liver injury, additional cases of vanishing bile duct syndrome, or new safety signals during the current reporting period.\n\nConclusions: The tREMS Program effectively mitigates hepatotoxicity risk through prompt intervention/reporting and timely dose modifications for adverse event management. When used according to guidelines, pexidartinib is a therapeutic option for adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.",
  "abstract_shown": true,
  "affiliations": [
    "Clinical Safety & Pharmacovigilance, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA",
    "Epidemiology, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA",
    "Global Oncology Medical Affairs, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Abdul Waheed Rajper",
      "orcid": "0009-0000-6468-7380"
    },
    {
      "affs": [
        1
      ],
      "name": "Charles Dharmani",
      "orcid": "0000-0003-3641-9738"
    },
    {
      "affs": [
        0
      ],
      "name": "Lalitha Chilakapati",
      "orcid": "0009-0009-0789-9956"
    },
    {
      "affs": [
        1
      ],
      "name": "Oluwatosin Fofah",
      "orcid": "0000-0003-2470-8276"
    },
    {
      "affs": [
        2
      ],
      "name": "Margaret J. Wooddell",
      "orcid": "0009-0008-3657-6614"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/apdb17h6szg9r.bib",
  "cited_by": 0,
  "doi": "10.1080/1179271x.2026.2757394",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13757696/",
  "id": "apdb17h6szg9r",
  "issns": [
    "1179-271X"
  ],
  "landing_url": "https://doi.org/10.1080/1179271x.2026.2757394",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Hepatology"
    ],
    [
      "heading",
      "Rapid Communication"
    ],
    [
      "openalex",
      "3004|Drug-Induced Hepatotoxicity and Protection"
    ]
  ],
  "openalex": "W7225308618",
  "pdf_url": "https://www.tandfonline.com/doi/pdf/10.1080/1179271X.2026.2757394?needAccess=true",
  "pmcid": "PMC13757696",
  "pmid": "43022703",
  "published": "2026-11-05",
  "publisher": "Taylor & Francis",
  "ris": "https://research.draconitic.com/paper/apdb17h6szg9r.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:23:17Z",
      "native_id": "PMC13757696",
      "source": "pmc",
      "url": "https://doi.org/10.1080/1179271x.2026.2757394"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:3004|Drug-Induced Hepatotoxicity and Protection",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "TURALIO Risk Evaluation and Mitigation Strategy Program: 6-year retrospective hepatic safety assessment",
  "title_text": "TURALIO Risk Evaluation and Mitigation Strategy Program: 6-year retrospective hepatic safety assessment",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:23:17Z",
  "url": "https://research.draconitic.com/paper/apdb17h6szg9r",
  "venue": "Patient Related Outcome Measures",
  "versions": []
}